MA40534B1 - Inhibiteurs de mk2 et leurs utilisations - Google Patents
Inhibiteurs de mk2 et leurs utilisationsInfo
- Publication number
- MA40534B1 MA40534B1 MA40534A MA40534A MA40534B1 MA 40534 B1 MA40534 B1 MA 40534B1 MA 40534 A MA40534 A MA 40534A MA 40534 A MA40534 A MA 40534A MA 40534 B1 MA40534 B1 MA 40534B1
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitors
- compositions
- compounds
- methods
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
La présente invention concerne des composés, leurs compositions et des méthodes pour les utiliser.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462051788P | 2014-09-17 | 2014-09-17 | |
US201562199927P | 2015-07-31 | 2015-07-31 | |
PCT/US2015/050495 WO2016044463A2 (fr) | 2014-09-17 | 2015-09-16 | Inhibiteurs de mk2 et leurs utilisations |
Publications (2)
Publication Number | Publication Date |
---|---|
MA40534A MA40534A (fr) | 2016-03-24 |
MA40534B1 true MA40534B1 (fr) | 2021-04-30 |
Family
ID=55454109
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA40534A MA40534B1 (fr) | 2014-09-17 | 2015-09-16 | Inhibiteurs de mk2 et leurs utilisations |
Country Status (30)
Country | Link |
---|---|
US (5) | US9458175B2 (fr) |
EP (2) | EP3193611B1 (fr) |
JP (3) | JP6556225B2 (fr) |
KR (1) | KR102457848B1 (fr) |
CN (1) | CN106998692B (fr) |
AU (1) | AU2015317741B2 (fr) |
BR (1) | BR112017005266B1 (fr) |
CA (1) | CA2961607C (fr) |
CL (1) | CL2017000576A1 (fr) |
CO (1) | CO2017003279A2 (fr) |
CY (1) | CY1124215T1 (fr) |
DK (1) | DK3193611T3 (fr) |
EA (1) | EA037299B1 (fr) |
EC (1) | ECSP17023281A (fr) |
ES (1) | ES2874561T3 (fr) |
HR (1) | HRP20210529T1 (fr) |
HU (1) | HUE054347T2 (fr) |
IL (1) | IL251051B (fr) |
LT (1) | LT3193611T (fr) |
MA (1) | MA40534B1 (fr) |
MX (2) | MX2017003359A (fr) |
NZ (1) | NZ730603A (fr) |
PL (1) | PL3193611T3 (fr) |
PT (1) | PT3193611T (fr) |
RS (1) | RS62017B1 (fr) |
SA (1) | SA517381115B1 (fr) |
SG (2) | SG11201701861RA (fr) |
SI (1) | SI3193611T1 (fr) |
TW (1) | TWI744217B (fr) |
WO (1) | WO2016044463A2 (fr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016518316A (ja) | 2013-03-15 | 2016-06-23 | セルジーン アビロミクス リサーチ, インコーポレイテッド | Mk2阻害剤およびそれらの使用 |
CA2961607C (fr) | 2014-09-17 | 2023-03-28 | Celgene Car Llc | Inhibiteurs de mk2 et leurs utilisations |
CN106632077B (zh) * | 2016-10-10 | 2019-01-22 | 上海再启生物技术有限公司 | 一种2-氨基-4-溴嘧啶的制备方法 |
WO2018170201A1 (fr) | 2017-03-16 | 2018-09-20 | Celgene Car Llc | Analogues deutérés d'inhibiteurs de mk2 et leurs utilisations |
WO2018170200A1 (fr) | 2017-03-16 | 2018-09-20 | Celgene Car Llc | Composés hétéroaryle utiles en tant qu'inhibiteurs de mk2 |
MX2019010642A (es) | 2017-03-16 | 2019-10-17 | Celgene Car Llc | Inhibidores de cinasa activada por mitogeno 2 (mk2), sintesis de los mismos, e intermediarios de los mismos. |
JP2020514361A (ja) * | 2017-03-16 | 2020-05-21 | セルジーン シーエーアール エルエルシー | 9,10,11,12−テトラヒドロ−8h−[1,4]ジアゼピノ[5’,6’:4,5]チエノ[3,2−f]キノリン−8−オン化合物およびその使用 |
CN110678178B (zh) * | 2017-03-16 | 2023-10-03 | 百时美施贵宝公司 | Mk2抑制剂的形式和组合物 |
CN107058259A (zh) * | 2017-05-18 | 2017-08-18 | 南京中医药大学 | 分子标志物mk2基因及其应用 |
US20220251105A1 (en) * | 2019-05-17 | 2022-08-11 | Celgene Car Llc | Methods of treating a mk2-mediated disorder |
CA3171335A1 (fr) * | 2020-02-14 | 2021-08-19 | Salk Institute For Biological Studies | Monotherapies et polytherapies avec des inhibiteurs de ulk1/2 |
US20230087078A1 (en) * | 2020-03-02 | 2023-03-23 | Washington University | Compositions and methods for the treatment of pancreatic cancer |
KR20230044446A (ko) * | 2020-07-24 | 2023-04-04 | 브리스톨-마이어스 스큅 컴퍼니 | 급성 호흡기 장애의 치료 방법 |
EP4079855A1 (fr) * | 2021-04-20 | 2022-10-26 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Composé et procédé pour la prophylaxie et le traitement de la leucémie |
TW202328141A (zh) * | 2021-08-27 | 2023-07-16 | 大陸商瑞石生物醫藥有限公司 | 喹啉并呋喃衍生物及其用途 |
WO2024044731A1 (fr) * | 2022-08-26 | 2024-02-29 | Matchpoint Therapeutics Inc. | Composés diazépino-thiéno-quinoxaline et leur utilisation en thérapie |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5015778A (en) | 1989-12-18 | 1991-05-14 | The Dow Chemical Company | Catalytic method to produce hydroxy substituted arylophenones |
WO1995026325A2 (fr) | 1994-03-25 | 1995-10-05 | Isotechnika Inc. | Potentialisation de medicaments par deuteration_______________ |
US5441946A (en) | 1994-04-14 | 1995-08-15 | Rhone-Poulenc-Rorer Pharmaceuticals, Inc. | Phosphonate derivatives of lipophilic amines |
GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
US6861440B2 (en) * | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
TW200413273A (en) | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
JP2006514043A (ja) | 2002-12-20 | 2006-04-27 | ファルマシア・コーポレーション | マイトジェン活性化タンパク質キナーゼ−活性化タンパク質キナーゼ−2を阻害する化合物 |
WO2005020921A2 (fr) | 2003-08-29 | 2005-03-10 | Exelixis, Inc. | Modulateurs c-kit et leurs procedes d'utilisation |
US20060106020A1 (en) | 2004-04-28 | 2006-05-18 | Rodgers James D | Tetracyclic inhibitors of Janus kinases |
JP4734346B2 (ja) | 2005-02-04 | 2011-07-27 | セノミックス インコーポレイテッド | 連結ヘテロアリール部分を含む化合物、ならびに食用組成物のための新規なうまみフレーバー改変剤、味物質および味覚増強剤としての使用 |
EP1849781A1 (fr) | 2006-04-28 | 2007-10-31 | Laboratorios del Dr. Esteve S.A. | Dérivés de 3-Amino-4-hydroxy pyrrolidine, procédé de fabrication et utilisation come medicaments |
EP2223925A1 (fr) | 2006-10-09 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Inhibiteurs de kinase |
AR067535A1 (es) | 2007-07-16 | 2009-10-14 | Novartis Ag | Derivados de lactama tetraciclicos |
WO2009055331A2 (fr) | 2007-10-22 | 2009-04-30 | Schering Corporation | Dérivés hétérocycliques bicycliques et leurs procédés d'utilisation |
MX360970B (es) | 2008-06-27 | 2018-11-23 | Avila Therapeutics Inc | Compuestos de heteroarilo y usos de los mismos. |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
WO2010048149A2 (fr) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Modulateurs hétérocycliques de gpr119 pour le traitement d'une maladie |
US20110269744A1 (en) * | 2010-03-12 | 2011-11-03 | Astellas Pharma Inc. | Benzazepine Compound |
WO2011153553A2 (fr) * | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Méthodes et compositions pour l'inhibition de kinases |
EP2508511A1 (fr) * | 2011-04-07 | 2012-10-10 | Laboratoire Biodim | Inhibiteurs de la réplication virale, leur procédé de préparation et leurs utilisations thérapeutiques |
EP2511273B8 (fr) * | 2011-04-15 | 2019-06-26 | Hivih | Inhibiteurs de la réplication virale, leur procédé de préparation et leurs utilisations thérapeutiques |
WO2013124040A1 (fr) | 2012-02-22 | 2013-08-29 | Merck Patent Gmbh | Milieu cristallin liquide |
US9187453B2 (en) * | 2012-03-28 | 2015-11-17 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
TW201406758A (zh) * | 2012-06-28 | 2014-02-16 | Daiichi Sankyo Co Ltd | 三環性化合物 |
EP2872144A4 (fr) * | 2012-07-11 | 2015-12-02 | Nimbus Iris Inc | Inhibiteurs d'irak et leurs utilisations |
MX2015003628A (es) * | 2012-09-24 | 2016-11-08 | Speede Claremont | Sistema y metodo de acceso de datos y de eliminacion de datos controlados por remitente movil. |
TW201417817A (zh) * | 2012-09-25 | 2014-05-16 | Daiichi Sankyo Co Ltd | Gsk3抑制劑與抗dr5抗體之組合 |
WO2014139144A1 (fr) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Composés et compositions thérapeutiques |
JP2016518316A (ja) | 2013-03-15 | 2016-06-23 | セルジーン アビロミクス リサーチ, インコーポレイテッド | Mk2阻害剤およびそれらの使用 |
WO2015050957A2 (fr) | 2013-10-02 | 2015-04-09 | Treatments For Systemic Lupus Erythematosus | Traitements du lupus érythémateux systémique |
WO2016032882A1 (fr) | 2014-08-25 | 2016-03-03 | Stc.Unm | Inhibition de mk2 dans le traitement du cancer |
CA2961607C (fr) | 2014-09-17 | 2023-03-28 | Celgene Car Llc | Inhibiteurs de mk2 et leurs utilisations |
RU2017128077A (ru) | 2015-01-08 | 2019-02-08 | Мори Матрикс, Инк. | Составы, содержащие пептиды, ингибирующие мк2 |
WO2018170201A1 (fr) | 2017-03-16 | 2018-09-20 | Celgene Car Llc | Analogues deutérés d'inhibiteurs de mk2 et leurs utilisations |
WO2018170200A1 (fr) | 2017-03-16 | 2018-09-20 | Celgene Car Llc | Composés hétéroaryle utiles en tant qu'inhibiteurs de mk2 |
CN110678178B (zh) | 2017-03-16 | 2023-10-03 | 百时美施贵宝公司 | Mk2抑制剂的形式和组合物 |
JP2020514361A (ja) | 2017-03-16 | 2020-05-21 | セルジーン シーエーアール エルエルシー | 9,10,11,12−テトラヒドロ−8h−[1,4]ジアゼピノ[5’,6’:4,5]チエノ[3,2−f]キノリン−8−オン化合物およびその使用 |
MX2019010642A (es) | 2017-03-16 | 2019-10-17 | Celgene Car Llc | Inhibidores de cinasa activada por mitogeno 2 (mk2), sintesis de los mismos, e intermediarios de los mismos. |
US20220251105A1 (en) | 2019-05-17 | 2022-08-11 | Celgene Car Llc | Methods of treating a mk2-mediated disorder |
KR20230044446A (ko) | 2020-07-24 | 2023-04-04 | 브리스톨-마이어스 스큅 컴퍼니 | 급성 호흡기 장애의 치료 방법 |
-
2015
- 2015-09-16 CA CA2961607A patent/CA2961607C/fr active Active
- 2015-09-16 NZ NZ730603A patent/NZ730603A/en unknown
- 2015-09-16 US US14/856,311 patent/US9458175B2/en active Active
- 2015-09-16 BR BR112017005266-0A patent/BR112017005266B1/pt active IP Right Grant
- 2015-09-16 TW TW104130645A patent/TWI744217B/zh active
- 2015-09-16 CN CN201580058026.4A patent/CN106998692B/zh active Active
- 2015-09-16 HU HUE15842903A patent/HUE054347T2/hu unknown
- 2015-09-16 RS RS20210725A patent/RS62017B1/sr unknown
- 2015-09-16 EP EP15842903.5A patent/EP3193611B1/fr active Active
- 2015-09-16 WO PCT/US2015/050495 patent/WO2016044463A2/fr active Application Filing
- 2015-09-16 EA EA201790380A patent/EA037299B1/ru not_active IP Right Cessation
- 2015-09-16 MX MX2017003359A patent/MX2017003359A/es active IP Right Grant
- 2015-09-16 LT LTEP15842903.5T patent/LT3193611T/lt unknown
- 2015-09-16 SI SI201531617T patent/SI3193611T1/sl unknown
- 2015-09-16 PL PL15842903T patent/PL3193611T3/pl unknown
- 2015-09-16 ES ES15842903T patent/ES2874561T3/es active Active
- 2015-09-16 DK DK15842903.5T patent/DK3193611T3/da active
- 2015-09-16 AU AU2015317741A patent/AU2015317741B2/en active Active
- 2015-09-16 JP JP2017515845A patent/JP6556225B2/ja active Active
- 2015-09-16 MA MA40534A patent/MA40534B1/fr unknown
- 2015-09-16 SG SG11201701861RA patent/SG11201701861RA/en unknown
- 2015-09-16 PT PT158429035T patent/PT3193611T/pt unknown
- 2015-09-16 EP EP21164056.0A patent/EP3912981A1/fr active Pending
- 2015-09-16 KR KR1020177010439A patent/KR102457848B1/ko active IP Right Grant
- 2015-09-16 SG SG10201902326XA patent/SG10201902326XA/en unknown
-
2016
- 2016-09-29 US US15/280,157 patent/US9790235B2/en active Active
-
2017
- 2017-03-09 IL IL25105117A patent/IL251051B/en active IP Right Grant
- 2017-03-09 CL CL2017000576A patent/CL2017000576A1/es unknown
- 2017-03-14 MX MX2020005213A patent/MX2020005213A/es unknown
- 2017-03-16 SA SA517381115A patent/SA517381115B1/ar unknown
- 2017-04-04 CO CONC2017/0003279A patent/CO2017003279A2/es unknown
- 2017-04-13 EC ECIEPI201723281A patent/ECSP17023281A/es unknown
- 2017-10-13 US US15/782,995 patent/US10253040B1/en active Active
-
2019
- 2019-04-04 US US16/375,317 patent/US10577380B2/en active Active
- 2019-07-09 JP JP2019127476A patent/JP2019194236A/ja active Pending
-
2020
- 2020-02-27 US US16/802,654 patent/US11584757B2/en active Active
-
2021
- 2021-03-31 HR HRP20210529TT patent/HRP20210529T1/hr unknown
- 2021-06-09 CY CY20211100504T patent/CY1124215T1/el unknown
-
2022
- 2022-03-16 JP JP2022041396A patent/JP7375072B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA40534B1 (fr) | Inhibiteurs de mk2 et leurs utilisations | |
EA201891200A1 (ru) | Композиции, содержащие бактериальные штаммы | |
PH12018500457A1 (en) | New phenoxymethyl derivatives | |
EA201890712A1 (ru) | Антитела к про-/латентному миостатину и их применения | |
EA201792205A1 (ru) | Гетероциклические соединения как ингибиторы lsd1 | |
EA201891251A1 (ru) | Бициклические ингибиторы pad4 | |
MX2018006148A (es) | Inhibidores de cxcr2. | |
EA201891910A1 (ru) | Гетероарильные ингибиторы pad4 | |
MX2015008999A (es) | Inhibidores mk2 y usos de los mismos. | |
EA201790173A1 (ru) | Антитела, связывающие axl | |
MX2022000053A (es) | Moduladores de interaccion de sestrina-gator2 y sus usos. | |
EA201691272A1 (ru) | Тетрагидропиридопиразины в качестве модуляторов gpr6 | |
MX2019011496A (es) | Composiciones de niraparib. | |
EA201692526A1 (ru) | Замещенные [1,2,4]триазольные соединения | |
EA201790184A1 (ru) | Пестицидные композиции | |
EA202091397A1 (ru) | Бензохинолоновые ингибиторы vmat2 | |
EA201691397A1 (ru) | Хинолиновые ингибиторы киназы | |
EA201891347A1 (ru) | Аза-бензимидазольные ингибиторы pad4 | |
MA41803A (fr) | Dérivés amino-indazoles utilisés comme inhibiteurs des canaux sodiques | |
TR201910057T4 (tr) | Kauçuk bi̇leşi̇mleri̇ | |
EA201600026A1 (ru) | Бактериальная гиалуронидаза и способ ее производства | |
MX2018007219A (es) | Metodos para preparacion de compuestos heterociclicos de 1,3-benzodioxol. | |
EA201691549A1 (ru) | Ариллактамные ингибиторы киназы | |
TW201613934A (en) | Methods for the preparation of 1,3-benzodioxole heterocyclic compounds | |
MA39824A (fr) | Composés azole amido-substitués |